Staff Reports
Here is a time line of key dates in Elanco Animal Health’s history:
1953: Eli Lilly and Co. introduces the first antibiotic exclusively for veterinary use.
1954: New plant and animal science activities are organized and combined into Lilly’s Agricultural and Industrial Sales Division.
1955: Eli Lilly and Co. purchases acreage adjoining the Biological Laboratories of Greenfield. The facility is completed in 1959 and opens as the Agricultural and Veterinary Medicine Research Center.
1956: With the purchase of Corn State Laboratories, Lilly expands its line of veterinary products.
1960: The Agricultural and Sales Division is reorganized, and Elanco Products Co. is launched.
1960s: Elanco expands its footprint by establishing agricultural units and opening up regional offices.
1970s: Elanco continues its global expansion and changes its identity with a new logo.
1980s: Research and development shifts from plant science toward animal health, specifically on increasing the quality of animal-sourced protein.
2000-2010: A new century brings new changes. Elanco moves its headquarters, acquires new partners, and rapidly grows the product portfolio.
2007: Elanco builds a dedicated global headquarters campus in Greenfield, bringing together employees from all areas of the company for the first time. It also acquires long-term partner Ivy Animal Health and launches its Pet Animal businesses.
2010: Elanco moves into its offices on Innovation Way in Greenfield.
2011: Elanco expands its European presence with the acquisition of Janssen Animal Health.
2012: With the acquisition of ChemGen, Elanco attains a portfolio of feed enzyme products for poultry, egg and meat production.
2013: Elanco completes the first expansion of its headquarters and establishes ‘hubs’ in international cities. The Pet Animal portfolio grows, and Elanco enters the vaccines sector.
2014: Elanco acquires Lohmann Animal Health and becomes a global leader in poultry.
2015: Elanco acquires Novartis Animal Health. The combined organization is committed to leading the animal health industry in delivering innovation and customer value.
2016: Elanco expands its U.S. pet health portfolio by acquiring a platform of vaccines from Boehringer Ingelheim Vetmedica.
2018: Elanco lists on the New York Stock Exchange (NYSE:ELAN), separating from Lilly and giving its employees ownership.
2019: Elanco becomes a fully-independent pure play animal health company. The company also launches its Healthy Purpose initiative: its corporate social responsibility platform, and commitment to realizing its vision of Food and Companionship Enriching Life. The Elanco Foundation is established, which is the first-ever charitable foundation in animal health. The company acquires Bayer Animal Health, making Elanco the world’s second-largest animal health company.
